1Rhode Island Infectious Diseases (RIID) Research Program, Veterans Affairs Medical Center, Providence, RI.
2University of Rhode Island, College of Pharmacy, Kingston, RI.
3Center of Innovation in Long-Term Services and Supports, Veterans Affairs Medical Center, Providence, RI.
4Brown University, Providence, RI.
5Albany College of Pharmacy and Health Sciences, Albany, NY.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Drs. Luther, Timbrook, and Dosa disclosed government work. Dr. Luther received other support from Pfizer, Cubist (Merck) research funding, and the Office of Academic Affiliations (VA) fellowship. Dr. Timbrook received other support from VA Office of Academic Affiliations fellowship, Biofire Diagnostics, GenMark Diagnostics, speaker and/or consultancy. Dr. Caffrey’s institution received funding from Pfizer, Merck, and the Medicines Company. Dr. Lodise received funding from Cubist (Merck), the Medicines Company, research funding, speaker, and/or consultancy. Dr. LaPlante received other funding from Pfizer, Cubist (Merck), Forest (Allergan), The Medicines Company, and Melinta research funding, speaker, and/or consultancy.
The work was supported, in part, by resources and use of facilities at the Providence Veterans Affairs Medical Center.
Presented, in part, as a poster (Number 1805) at IDweek 2016, New Orleans, LA, October 29, 2016.
The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government.
For information regarding this article, E-mail: [email protected]